JP2020513811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513811A5 JP2020513811A5 JP2019550767A JP2019550767A JP2020513811A5 JP 2020513811 A5 JP2020513811 A5 JP 2020513811A5 JP 2019550767 A JP2019550767 A JP 2019550767A JP 2019550767 A JP2019550767 A JP 2019550767A JP 2020513811 A5 JP2020513811 A5 JP 2020513811A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- muscular dystrophy
- item
- recombinant
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 32
- 239000002773 nucleotide Substances 0.000 claims description 27
- 125000003729 nucleotide group Chemical group 0.000 claims description 27
- 201000006938 muscular dystrophy Diseases 0.000 claims description 25
- 210000003205 muscle Anatomy 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 239000013607 AAV vector Substances 0.000 description 33
- 238000000034 method Methods 0.000 description 14
- 239000003623 enhancer Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 101001044938 Dictyostelium discoideum Diacylglycerol kinase A Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010051583 Ventricular Myosins Proteins 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 241000649047 Adeno-associated virus 12 Species 0.000 description 1
- 241000300529 Adeno-associated virus 13 Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102100024108 Dystrophin Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102000011856 Utrophin Human genes 0.000 description 1
- 108010075653 Utrophin Proteins 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023019888A JP2023053254A (ja) | 2017-03-17 | 2023-02-13 | 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| JP2024229759A JP2025061676A (ja) | 2017-03-17 | 2024-12-26 | 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762473148P | 2017-03-17 | 2017-03-17 | |
| US62/473,148 | 2017-03-17 | ||
| PCT/US2018/022881 WO2018170408A1 (en) | 2017-03-17 | 2018-03-16 | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019888A Division JP2023053254A (ja) | 2017-03-17 | 2023-02-13 | 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| JP2024229759A Division JP2025061676A (ja) | 2017-03-17 | 2024-12-26 | 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513811A JP2020513811A (ja) | 2020-05-21 |
| JP2020513811A5 true JP2020513811A5 (enExample) | 2021-04-22 |
| JP7676111B2 JP7676111B2 (ja) | 2025-05-14 |
Family
ID=63523321
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550767A Active JP7676111B2 (ja) | 2017-03-17 | 2018-03-16 | 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| JP2023019888A Pending JP2023053254A (ja) | 2017-03-17 | 2023-02-13 | 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| JP2024229759A Pending JP2025061676A (ja) | 2017-03-17 | 2024-12-26 | 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019888A Pending JP2023053254A (ja) | 2017-03-17 | 2023-02-13 | 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| JP2024229759A Pending JP2025061676A (ja) | 2017-03-17 | 2024-12-26 | 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
Country Status (33)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11617783B2 (en) | 2015-11-16 | 2023-04-04 | Research Institute At Nationwide Children's Hospital | Repairing a mutant human titin gene using CRISPR technology |
| WO2019012336A2 (en) | 2017-03-17 | 2019-01-17 | Newcastle University | ADENO-ASSOCIATED VIRAL VECTOR DELIVERY OF A MICRO-DYSTROPHIN FRAGMENT FOR TREATING MUSCLE DYSTROPHY |
| CN111433367A (zh) | 2017-10-20 | 2020-07-17 | 全国儿童医院研究所 | Nt-3基因疗法的方法和材料 |
| AU2019216257B2 (en) | 2018-01-31 | 2025-11-20 | Research Institute At Nationwide Children's Hospital | Gene therapy for limb-girdle muscular dystrophy type 2C |
| EP4591888A3 (en) * | 2018-06-18 | 2026-01-21 | Research Institute at Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
| US12391928B2 (en) | 2018-06-29 | 2025-08-19 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A |
| CA3124415A1 (en) * | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| CA3146364A1 (en) * | 2019-02-02 | 2020-08-06 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | One-step gene therapy for duchenne muscular dystrophy via gene replacement and anti-inflammation |
| CN113766935A (zh) | 2019-02-26 | 2021-12-07 | 全国儿童医院研究所 | β-肌聚糖的腺相关病毒载体递送和肌营养不良症的治疗 |
| AU2020284255A1 (en) * | 2019-05-30 | 2022-01-06 | Solid Biosciences Inc. | Recombinant herpesvirales vector |
| SI4017871T1 (sl) | 2019-08-21 | 2024-06-28 | Research Institute At Nationwide Children's Hospital | Dostava alfa-sarkoglikana z adeno povezanim virusnim vektorjem in zdravljenje mišične distrofije |
| WO2021042004A1 (en) * | 2019-08-29 | 2021-03-04 | Siemens Healthcare Diagnostics Inc. | Reagents and methods for detecting aav shedding |
| EP4065596A2 (en) * | 2019-11-28 | 2022-10-05 | RegenxBio Inc. | Microdystrophin gene therapy constructs and uses thereof |
| US20230040544A1 (en) * | 2019-12-16 | 2023-02-09 | Research Institute At Nationwide Children's Hospital | Compositions and methods for restoring and maintaining the dystrophin-associated protein complex (dapc) |
| WO2021222332A1 (en) | 2020-04-29 | 2021-11-04 | Bristol-Myers Squibb Company | Miniaturized dystrophins having spectrin fusion domains and uses thereof |
| JP2023536618A (ja) * | 2020-08-05 | 2023-08-28 | スペースクラフト セブン リミテッド ライアビリティ カンパニー | Ｃｓｒｐ３（システイン及びグリシンリッチタンパク質３）遺伝子治療 |
| WO2022029543A1 (en) * | 2020-08-06 | 2022-02-10 | Intas Pharmaceuticals Ltd. | Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy |
| WO2022104062A1 (en) * | 2020-11-12 | 2022-05-19 | Precision Biosciences, Inc. | Engineered meganucleases having specificity for recognition sequences in the dystrophin gene |
| EP4086276A1 (en) | 2021-05-03 | 2022-11-09 | Université d'Aix-Marseille | Composition for treating dysferlinopathy |
| EP4108263A3 (en) * | 2021-06-02 | 2023-03-22 | Research Institute at Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a |
| CA3224482A1 (en) * | 2021-08-05 | 2023-02-09 | Brian Kaspar | Adeno-associated virus particles and methods of use thereof |
| JP2024531138A (ja) * | 2021-08-11 | 2024-08-29 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 筋ジストロフィーを処置するための組成物および方法 |
| EP4219726A1 (en) | 2021-10-15 | 2023-08-02 | Research Institute at Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
| CN114316070B (zh) * | 2021-12-29 | 2022-11-15 | 上海勉亦生物科技有限公司 | 用于治疗肌营养不良症的转基因表达盒 |
| EP4215614A1 (en) | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
| EP4509606A4 (en) * | 2022-04-19 | 2025-12-10 | Kanglin Biotech Hangzhou Co Ltd | CONSTRUCTION OF NUCLEIC ACID FOR THE TREATMENT OF AN INHERITED COAGULATION FACTOR DEFICIENCY AND ITS USE |
| WO2023248251A1 (en) * | 2022-06-24 | 2023-12-28 | Indian Institute Of Technology Kanpur | An optimized aav vector for gene therapy of muscular dystrophy |
| CN115819546B (zh) * | 2022-08-19 | 2025-12-05 | 成都金唯科生物科技有限公司 | 表达微缩抗肌营养不良蛋白基因的腺相关病毒载体及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| DE69433592T2 (de) | 1993-11-09 | 2005-02-10 | Targeted Genetics Corp., Seattle | Die erzielung hoher titer des rekombinanten aav-vektors |
| WO1995013392A1 (en) | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| EP0796339A1 (en) | 1994-12-06 | 1997-09-24 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| AU722196B2 (en) | 1995-08-30 | 2000-07-27 | Genzyme Corporation | Chromatographic purification of adenovirus and AAV |
| CA2230758A1 (en) | 1995-09-08 | 1997-03-13 | Genzyme Corporation | Improved aav vectors for gene therapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| CN1233291A (zh) | 1996-09-06 | 1999-10-27 | 宾西法尼亚大学托管会 | 重组腺伴随病毒定向基因治疗的方法 |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| WO1999011764A2 (en) | 1997-09-05 | 1999-03-11 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| JP2004514407A (ja) | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| WO2003052051A2 (en) | 2001-12-17 | 2003-06-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
| US20080044393A1 (en) * | 2004-07-16 | 2008-02-21 | White Robert L | Retinal dystrophin transgene and methods of use thereof |
| DK2203173T3 (en) * | 2007-10-26 | 2016-02-29 | Academisch Ziekenhuis Leiden | Materials and methods for prevention of muscle diseases |
| ES2593836T3 (es) * | 2009-04-24 | 2016-12-13 | Biomarin Technologies B.V. | Oligonucleótido que comprende una inosina para tratar la DMD |
| CA2842798C (en) | 2011-07-25 | 2021-02-23 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
| JP2015503924A (ja) | 2012-01-05 | 2015-02-05 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | 遺伝子導入のための方法及び組成物 |
| WO2013123503A1 (en) | 2012-02-17 | 2013-08-22 | The Children's Hospital Of Philadelphia | Aav vector compositions and methods for gene transfer to cells, organs and tissues |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| EP2986632B1 (en) * | 2013-04-20 | 2018-09-05 | Research Institute at Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| WO2015110449A1 (en) | 2014-01-21 | 2015-07-30 | Vrije Universiteit Brussel | Muscle-specific nucleic acid regulatory elements and methods and use thereof |
| WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
| EP2960336A1 (en) * | 2014-06-27 | 2015-12-30 | Genethon | Efficient systemic treatment of dystrophic muscle pathologies |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| GB201507842D0 (en) * | 2015-05-07 | 2015-06-17 | New Royal Holloway & Bedford | Production of large-sized microdystrophins in an AAV-based vector configuration |
| JP7153562B2 (ja) * | 2016-04-15 | 2022-10-14 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 筋ジストロフィーを治療するためのマイクロｒｎａ－２９のアデノ随伴ウイルスベクター送達 |
-
2018
- 2018-03-16 DK DK18768395.8T patent/DK3596222T5/da active
- 2018-03-16 IL IL311713A patent/IL311713B2/en unknown
- 2018-03-16 CN CN202311798281.5A patent/CN118497275A/zh active Pending
- 2018-03-16 KR KR1020247022488A patent/KR102887103B1/ko active Active
- 2018-03-16 HR HRP20230522TT patent/HRP20230522T1/hr unknown
- 2018-03-16 PT PT187683958T patent/PT3596222T/pt unknown
- 2018-03-16 HU HUE18768395A patent/HUE062476T2/hu unknown
- 2018-03-16 SI SI201830926T patent/SI3596222T1/sl unknown
- 2018-03-16 EA EA201992201A patent/EA201992201A1/ru unknown
- 2018-03-16 SM SM20230201T patent/SMT202300201T1/it unknown
- 2018-03-16 ES ES18768395T patent/ES2948233T3/es active Active
- 2018-03-16 KR KR1020257037800A patent/KR20250163423A/ko active Pending
- 2018-03-16 WO PCT/US2018/022881 patent/WO2018170408A1/en not_active Ceased
- 2018-03-16 JP JP2019550767A patent/JP7676111B2/ja active Active
- 2018-03-16 BR BR112019019248A patent/BR112019019248A2/pt unknown
- 2018-03-16 LT LTEPPCT/US2018/022881T patent/LT3596222T/lt unknown
- 2018-03-16 IL IL269391A patent/IL269391B2/en unknown
- 2018-03-16 KR KR1020197029367A patent/KR102683682B1/ko active Active
- 2018-03-16 MA MA52112A patent/MA52112B1/fr unknown
- 2018-03-16 MX MX2019011046A patent/MX2019011046A/es unknown
- 2018-03-16 EP EP23167357.5A patent/EP4245852A3/en active Pending
- 2018-03-16 AU AU2018233732A patent/AU2018233732B2/en active Active
- 2018-03-16 IL IL320791A patent/IL320791A/en unknown
- 2018-03-16 CA CA3056638A patent/CA3056638A1/en active Pending
- 2018-03-16 RS RS20230434A patent/RS64299B1/sr unknown
- 2018-03-16 FI FIEP18768395.8T patent/FI3596222T3/fi active
- 2018-03-16 CN CN201880018893.9A patent/CN110997923B/zh active Active
- 2018-03-16 US US16/494,614 patent/US20200199621A1/en not_active Abandoned
- 2018-03-16 EP EP18768395.8A patent/EP3596222B1/en active Active
- 2018-03-16 MD MDE20200102T patent/MD3596222T2/ro unknown
- 2018-03-16 SG SG11201908575S patent/SG11201908575SA/en unknown
- 2018-03-16 MY MYPI2019005365A patent/MY203547A/en unknown
- 2018-03-16 PL PL18768395.8T patent/PL3596222T3/pl unknown
- 2018-03-19 TW TW114108403A patent/TW202525835A/zh unknown
- 2018-03-19 TW TW107109334A patent/TWI878204B/zh active
- 2018-03-19 AR ARP180100629A patent/AR111292A1/es unknown
-
2019
- 2019-09-17 MX MX2025007401A patent/MX2025007401A/es unknown
- 2019-09-17 SA SA519410146A patent/SA519410146B1/ar unknown
- 2019-09-17 MX MX2025007402A patent/MX2025007402A/es unknown
- 2019-09-20 ZA ZA2019/06251A patent/ZA201906251B/en unknown
- 2019-10-10 CO CONC2019/0011250A patent/CO2019011250A2/es unknown
-
2022
- 2022-06-03 US US17/832,325 patent/US20220364117A1/en active Pending
-
2023
- 2023-02-13 JP JP2023019888A patent/JP2023053254A/ja active Pending
- 2023-06-21 CY CY20231100291T patent/CY1126080T1/el unknown
-
2024
- 2024-11-19 AU AU2024266707A patent/AU2024266707B2/en active Active
- 2024-12-26 JP JP2024229759A patent/JP2025061676A/ja active Pending
-
2025
- 2025-01-22 AU AU2025200437A patent/AU2025200437A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513811A5 (enExample) | ||
| JP2020510447A5 (enExample) | ||
| JP2019513393A5 (enExample) | ||
| JP2019513399A5 (enExample) | ||
| JP2019513389A5 (enExample) | ||
| JP2021500352A5 (enExample) | ||
| JP2019513779A5 (enExample) | ||
| JP2025162557A5 (enExample) | ||
| TWI878204B (zh) | 腺相關病毒載體遞送肌肉特異性微小肌縮蛋白以治療肌肉萎縮症 | |
| IL320714A (en) | Gene therapy for limb-girdle muscular dystrophy type 2c | |
| JP7213238B2 (ja) | 筋ジストロフィーを治療するための筋特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 | |
| JP2019536782A5 (enExample) | ||
| JP2020533959A5 (enExample) | ||
| GB2590880A (en) | RNA and DNA base editing via engineered ADAR recruitment | |
| JPWO2021077000A5 (enExample) | ||
| JP2018527365A5 (enExample) | ||
| JPWO2019152474A5 (enExample) | ||
| JP2017529395A5 (enExample) | ||
| JP2024159800A (ja) | 筋肉発現のためのハイブリッドプロモーター | |
| RU2018121289A (ru) | Способы лечения мышечной дистрофии | |
| WO2020142714A1 (en) | Aav expression cassette and aav vectors comprising the same | |
| JPWO2020006458A5 (enExample) | ||
| JP2020510433A5 (enExample) | ||
| JPWO2020186150A5 (enExample) | ||
| JP2023059858A5 (enExample) |